Core Laboratories Inc.
CLB
$13.36
$0.181.33%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 121.80M | 138.26M | 134.52M | 130.16M | 123.59M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 121.80M | 138.26M | 134.52M | 130.16M | 123.59M |
| Cost of Revenue | 102.07M | 109.52M | 104.90M | 103.70M | 99.47M |
| Gross Profit | 19.72M | 28.74M | 29.62M | 26.46M | 24.12M |
| SG&A Expenses | 14.37M | 10.32M | 10.38M | 10.16M | 13.37M |
| Depreciation & Amortization | 3.76M | 3.67M | 3.59M | 3.67M | 3.72M |
| Other Operating Expenses | -380.00K | -358.00K | -375.00K | -144.00K | -785.00K |
| Total Operating Expenses | 119.83M | 123.15M | 118.50M | 117.39M | 115.77M |
| Operating Income | 1.97M | 15.11M | 16.03M | 12.77M | 7.82M |
| Income Before Tax | -1.00M | 13.22M | 18.28M | 12.58M | 1.82M |
| Income Tax Expenses | -251.00K | 8.09M | 3.75M | 1.91M | 1.75M |
| Earnings from Continuing Operations | -753.00K | 5.13M | 14.52M | 10.67M | 69.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -36.00K | -181.00K | -285.00K | -33.00K | -223.00K |
| Net Income | -789.00K | 4.95M | 14.24M | 10.64M | -154.00K |
| EBIT | 1.97M | 15.11M | 16.03M | 12.77M | 7.82M |
| EBITDA | 5.74M | 18.78M | 19.62M | 16.44M | 11.53M |
| EPS Basic | -0.02 | 0.11 | 0.31 | 0.23 | 0.00 |
| Normalized Basic EPS | -0.02 | 0.16 | 0.17 | 0.13 | 0.06 |
| EPS Diluted | -0.02 | 0.11 | 0.30 | 0.22 | 0.00 |
| Normalized Diluted EPS | -0.02 | 0.16 | 0.16 | 0.13 | 0.06 |
| Average Basic Shares Outstanding | 46.07M | 46.70M | 46.26M | 46.63M | 46.77M |
| Average Diluted Shares Outstanding | 46.07M | 46.70M | 47.08M | 47.36M | 46.77M |
| Dividend Per Share | -- | 0.01 | 0.01 | 0.01 | 0.01 |
| Payout Ratio | -58.30% | 9.42% | 3.27% | 4.41% | -304.55% |